Ultimovacs to Progress to Last Cohort in Phase I Prostate Cancer TENDU study

Ultimovacs announced it has completed treatment of the second dose cohort in the Phase I TENDU trial. The study is designed to evaluate the company’s tetanus-epitope targeting-platform in patients with prostate cancer.